Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 50,889,616
  • Shares Outstanding, K 3,929,700
  • Annual Sales, $ 50,432 M
  • Annual Income, $ -2,762 M
  • EBIT $ 3,627 M
  • EBITDA $ 13,131 M
  • 60-Month Beta 0.66
  • Price/Sales 1.01
  • Price/Cash Flow 3.21
  • Price/Book 1.38
  • Price/Earnings ttm 8.39
  • Earnings Per Share ttm 1.45
  • Most Recent Earnings $0.17 on 11/12/25
  • Next Earnings Date 03/04/26
  • Annual Dividend & Yield (Fwd) 0.02 (0.19%)
  • Most Recent Dividend 0.023 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.17
  • Number of Estimates 2
  • High Estimate 0.19
  • Low Estimate 0.15
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -39.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.2200 +26.71%
on 12/17/25
13.0000 -0.38%
on 01/16/26
+2.6642 (+25.90%)
since 12/16/25
3-Month
7.4790 +73.15%
on 11/04/25
13.0000 -0.38%
on 01/16/26
+5.1100 (+65.18%)
since 10/16/25
52-Week
5.3000 +144.34%
on 04/07/25
13.0000 -0.38%
on 01/16/26
+7.6000 (+142.06%)
since 01/16/25

Most Recent Stories

More News
Bayer Accelerates Pharma Growth on High-Value Portfolio

Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

Not intended for UK Media Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Introducing Sivanto Energy: Enhanced Flea Beetle Control

Bayer Crop Science Canada is excited to announce the launch of Sivanto® Energy, a groundbreaking foliar insecticide designed to deliver swift, reliable pest control with extended protection. Formulated...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control

Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control...

BAYRY : 12.9500 (+6.41%)
BAYZF : 51.9500 (+6.50%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 14.3667
2nd Resistance Point 13.6833
1st Resistance Point 13.3167
Last Price 12.9500
1st Support Level 12.2667
2nd Support Level 11.5833
3rd Support Level 11.2167

See More

52-Week High 13.0000
Last Price 12.9500
Fibonacci 61.8% 10.0586
Fibonacci 50% 9.1500
Fibonacci 38.2% 8.2414
52-Week Low 5.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar